Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
AJNR. American Journal of Neuroradiology
|
March 2, 2013
Facet joint signal change on MRI at levels of acute/subacute lumbar compression fractures
V T Lehman, C P Wood, C H Hunt, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes
|
October 27, 2021
<i>BRAF</i> V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)
Jessica A Slostad, Minetta C Liu, Jacob B Allred, et al.
Melanoma Research
|
March 16, 2017
Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma
Roberto A Leon-Ferre, Lisa A Kottschade, Matthew S Block, et al.
Clinical Breast Cancer
|
March 27, 2012
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial
Winston W Tan, Jacob B Allred, Muhammad Salim, et al.
The Oncologist
|
April 19, 2018
Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance)
Jesus Vera Aguilera, Ravi D Rao, Jacob B Allred, et al.
Clinical Breast Cancer
|
October 23, 2012
North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane
Kostandinos Sideras, Amylou C Dueck, Timothy J Hobday, et al.
Immunotherapy
|
August 6, 2020
Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma
Eric P Grewal, Courtney L Erskine, Wendy K Nevala, et al.
Leukemia & Lymphoma
|
July 7, 2007
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51
David M Kurtz, Loren K Tschetter, Jacob B Allred, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2019
Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)
Jason J Luke, Daniel J Olson, Jacob B Allred, et al.
American Journal of Clinical Oncology
|
August 8, 2006
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization
Svetomir N Markovic, Vera J Suman, James N Ingle, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
AJNR. American Journal of Neuroradiology
|
March 2, 2013
Facet joint signal change on MRI at levels of acute/subacute lumbar compression fractures
V T Lehman, C P Wood, C H Hunt, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes
|
October 27, 2021
<i>BRAF</i> V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)
Jessica A Slostad, Minetta C Liu, Jacob B Allred, et al.
Melanoma Research
|
March 16, 2017
Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma
Roberto A Leon-Ferre, Lisa A Kottschade, Matthew S Block, et al.
Clinical Breast Cancer
|
March 27, 2012
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial
Winston W Tan, Jacob B Allred, Muhammad Salim, et al.
The Oncologist
|
April 19, 2018
Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance)
Jesus Vera Aguilera, Ravi D Rao, Jacob B Allred, et al.
Clinical Breast Cancer
|
October 23, 2012
North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane
Kostandinos Sideras, Amylou C Dueck, Timothy J Hobday, et al.
Immunotherapy
|
August 6, 2020
Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma
Eric P Grewal, Courtney L Erskine, Wendy K Nevala, et al.
Leukemia & Lymphoma
|
July 7, 2007
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51
David M Kurtz, Loren K Tschetter, Jacob B Allred, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2019
Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)
Jason J Luke, Daniel J Olson, Jacob B Allred, et al.
American Journal of Clinical Oncology
|
August 8, 2006
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization
Svetomir N Markovic, Vera J Suman, James N Ingle, et al.
Page
of 8